• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

作者信息

Tedde R, Pala A, Melis A, Ulick S

机构信息

Clinica Medica, Università di Sassari, Italy.

出版信息

J Endocrinol Invest. 1992 Jun;15(6):471-4. doi: 10.1007/BF03348778.

DOI:10.1007/BF03348778
PMID:1401749
Abstract

The hypothesis that cortisol is the functioning mineralocorticoid in the syndrome of apparent mineralocorticoid excess was tested by suppressing its secretion with dexamethasone. The subjects were two siblings with the type 2 form of this syndrome in which the defect in the peripheral metabolism of cortisol lies predominantly in ring A reduction but not in 11 beta-hydroxy dehydrogenation of cortisol to cortisone. Low dosage dexamethasone improved the hypokalemia within several days and hypertension was corrected after 3 weeks of treatment. Mineralocorticoid manifestations remained in remission during 10 yr of therapy with the synthetic glucocorticoid during which normal growth and development were restored. The effectiveness of dexamethasone supports the hypothesis that cortisol is the functioning mineralocorticoid in the AME syndrome.

摘要

相似文献

1
Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.
J Endocrinol Invest. 1992 Jun;15(6):471-4. doi: 10.1007/BF03348778.
2
Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.表观盐皮质激素过多综合征。皮质醇 - 可的松穿梭缺陷。
J Clin Invest. 1988 Jul;82(1):340-9. doi: 10.1172/JCI113592.
3
Apparent mineralocorticoid excess: type I and type II.表观盐皮质激素过多症:I型和II型。
Steroids. 1996 Apr;61(4):193-6. doi: 10.1016/0039-128x(96)00012-8.
4
Apparent mineralocorticoid excess syndromes.表观盐皮质激素过多综合征
J Endocrinol Invest. 1995 Jul-Aug;18(7):518-32. doi: 10.1007/BF03349763.
5
Apparent mineralocorticoid excess type II.
Steroids. 1994 Feb;59(2):80-3. doi: 10.1016/0039-128x(94)90080-9.
6
[Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].[11β-羟类固醇脱氢酶缺乏所致表观盐皮质激素过多综合征:对一个智利家族进行19年随访的临床与遗传学研究]
Rev Med Chil. 2000 Jan;128(1):17-26.
7
Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.缺陷环:皮质醇减少是表观盐皮质激素过多综合征中的主要代谢错误。
J Clin Endocrinol Metab. 1992 Mar;74(3):593-9. doi: 10.1210/jcem.74.3.1740492.
8
Apparent mineralocorticoid excess syndrome: report of one family with three affected children.表观盐皮质激素过多综合征:一个有三名患病儿童的家庭报告。
J Pediatr Endocrinol Metab. 2012;25(11-12):1083-8. doi: 10.1515/jpem-2012-0113.
9
The syndrome of apparent mineralocorticoid excess.表象性盐皮质激素增多综合征
QJM. 1998 Jul;91(7):453-5. doi: 10.1093/qjmed/91.7.453.
10
Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome.
J Clin Endocrinol Metab. 1992 May;74(5):963-7. doi: 10.1210/jcem.74.5.1569172.

引用本文的文献

1
Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.表观盐皮质激素过多“II型变异型”高血压的分子基础。
Am J Hum Genet. 1998 Aug;63(2):370-9. doi: 10.1086/301955.
2
Apparent mineralocorticoid excess syndromes.表观盐皮质激素过多综合征
J Endocrinol Invest. 1995 Jul-Aug;18(7):518-32. doi: 10.1007/BF03349763.

本文引用的文献

1
Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child.一名19个月大儿童的低肾素、低醛固酮性高血压及异常皮质醇代谢
Horm Res. 1982;16(2):107-14. doi: 10.1159/000179490.
2
Fatal, low renin hypertension associated with a disturbance of cortisol metabolism.与皮质醇代谢紊乱相关的致命性低肾素性高血压。
Arch Dis Child. 1983 Dec;58(12):1018-20. doi: 10.1136/adc.58.12.1018.
3
Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess.
J Clin Endocrinol Metab. 1983 Feb;56(2):332-9. doi: 10.1210/jcem-56-2-332.
4
Apparent mineralocorticoid excess and deficient 11 beta-oxidation of cortisol in a young female.
Clin Endocrinol (Oxf). 1984 Nov;21(5):505-14. doi: 10.1111/j.1365-2265.1984.tb01388.x.
5
Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.表观盐皮质激素过多综合征。皮质醇 - 可的松穿梭缺陷。
J Clin Invest. 1988 Jul;82(1):340-9. doi: 10.1172/JCI113592.
6
Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.人盐皮质激素受体互补DNA的克隆:与糖皮质激素受体的结构和功能关系
Science. 1987 Jul 17;237(4812):268-75. doi: 10.1126/science.3037703.
7
A new form of the syndrome of apparent mineralocorticoid excess.
J Steroid Biochem. 1989 Jan;32(1B):209-12. doi: 10.1016/0022-4731(89)90166-0.
8
Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor.11β-羟类固醇脱氢酶的定位——盐皮质激素受体的组织特异性保护因子
Lancet. 1988 Oct 29;2(8618):986-9. doi: 10.1016/s0140-6736(88)90742-8.
9
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.盐皮质激素作用:靶组织特异性是由酶介导而非受体介导的。
Science. 1988 Oct 28;242(4878):583-5. doi: 10.1126/science.2845584.
10
Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess.
J Clin Endocrinol Metab. 1990 Jan;70(1):200-6. doi: 10.1210/jcem-70-1-200.